Scoring system to predict response to IFN-β in patients with multiple sclerosis

被引：0
|
作者：
机构：
来源：
Nature Reviews Neurology | 2012年 / 8卷 / 11期
关键词：
D O I：
10.1038/nrneurol.2012.216
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：594 / 594
相关论文
共 50 条
  • [31] A little stress is good:: IFN-γ, demyelination, and multiple sclerosis
    Lees, Jason R.
    Cross, Anne H.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (02): : 297 - 299
  • [32] Gene Expression Biomarkers for IFN-β Treatment Response in Relapsing-Remitting Multiple Sclerosis
    Anis, Saar
    Sonis, Polina
    Hanael, Erez
    Gurevich, Michael
    Achiron, Anat
    NEUROLOGY, 2013, 80
  • [33] The safety and efficacy of IFN-β products for the treatment of multiple sclerosis
    Kremenchutzky, Marcelo
    Morrow, Sarah
    Rush, Carolina
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (03) : 279 - 288
  • [34] Neutralizing and binding antibodies to IFN-β:: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations
    Scagnolari, C
    Bellomi, F
    Turriziani, O
    Bagnato, F
    Tomassini, V
    Lavolpe, V
    Ruggieri, M
    Bruschi, F
    Meucci, G
    Dicuonzo, G
    Antonelli, G
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (02): : 207 - 213
  • [35] IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
    Sweeney, Cheryl M.
    Lonergan, Roisin
    Basdeo, Sharee A.
    Kinsella, Katie
    Dungan, Lara S.
    Higgins, Sarah C.
    Kelly, Patrick J.
    Costelloe, Lisa
    Tubridy, Niall
    Mills, Kingston H. G.
    Fletcher, Jean M.
    BRAIN BEHAVIOR AND IMMUNITY, 2011, 25 (06) : 1170 - 1181
  • [36] IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
    Sweeney, C. M.
    Lonergan, R.
    Basdeo, S. A.
    Dungan, L. S.
    Kinsella, K.
    Costelloe, L.
    Tubridy, N.
    Fletcher, J. M.
    Mills, K. H. G.
    IMMUNOLOGY, 2010, 131 : 36 - 36
  • [37] Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients
    Adriani, Marsilio
    Nytrova, Petra
    Mbogning, Cyprien
    Hassler, Signe
    Medek, Karel
    Jensen, Poul Erik H.
    Creeke, Paul
    Warnke, Clemens
    Ingenhoven, Kathleen
    Hemmer, Bernhard
    Sievers, Claudia
    Gasser, Raija L. P. Lindberg
    Fissolo, Nicolas
    Deisenhammer, Florian
    Bocskei, Zsolt
    Mikol, Vincent
    Fogdell-Hahn, Anna
    Havrdova, Eva Kubala
    Broet, Philippe
    Donnes, Pierre
    Mauri, Claudia
    Jury, Elizabeth C.
    JCI INSIGHT, 2018, 3 (11):
  • [38] TLR responsiveness of B cells is modulated in patients with multiple sclerosis following IFN-β therapy
    Elena, Severa M. Giacomini
    Rizzo, F.
    Remoli, M. E.
    Gafa, V.
    Romano, S.
    Mechelli, R.
    Salvetti, M.
    Coccia, E. M.
    CYTOKINE, 2011, 56 (01) : 18 - 18
  • [39] Cell type-specific responses to IFN-β: Implications for understanding the mechanism of IFN-β therapy in multiple sclerosis
    van Boxel-Dezaire, Anette H. H.
    Fisher, Elizabeth
    Ransohoff, Richard M.
    Rudick, Richard A.
    Stark, George R.
    CYTOKINE, 2010, 52 (1-2) : 40 - 40
  • [40] Pharmacogenomics of the response to IFN-β in multiple sclerosis:: ramifications from the first genome-wide screen
    Vandenbroeck, Koen
    Matute, Carlos
    PHARMACOGENOMICS, 2008, 9 (05) : 639 - 645
12345